<code id='C741143FA2'></code><style id='C741143FA2'></style>
    • <acronym id='C741143FA2'></acronym>
      <center id='C741143FA2'><center id='C741143FA2'><tfoot id='C741143FA2'></tfoot></center><abbr id='C741143FA2'><dir id='C741143FA2'><tfoot id='C741143FA2'></tfoot><noframes id='C741143FA2'>

    • <optgroup id='C741143FA2'><strike id='C741143FA2'><sup id='C741143FA2'></sup></strike><code id='C741143FA2'></code></optgroup>
        1. <b id='C741143FA2'><label id='C741143FA2'><select id='C741143FA2'><dt id='C741143FA2'><span id='C741143FA2'></span></dt></select></label></b><u id='C741143FA2'></u>
          <i id='C741143FA2'><strike id='C741143FA2'><tt id='C741143FA2'><pre id='C741143FA2'></pre></tt></strike></i>

          knowledge

          knowledge

          author:Wikipedia    Page View:81111

          Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do you pronounce bronchiectasis?

          This week on “The Readout LOUD,” we preview some of the research that will be presented at the American Society of Clinical Oncology conference in Chicago. We also discuss the latest news in the health and life sciences, including a milestone in lung disease R&D and a Duchenne muscular dystrophy confirmatory trial failure.  

          advertisement

          To read more about Merus’ combination therapy, go here; For more on Johnson & Johnson’s mixed data, click here; For more on Nippon Shinyaku’s Duchenne drug trial failure, go here; To read more on Insmed’s bronchiectasis treatment, click here; To sign up for STAT’s ASCO newsletter, click here.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          comprehensive

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?
          Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Readout Newsletter: The latest at Gilead, Catalent, and the NIH

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb